Why the study?
Does extended prophylaxis with aspirin prevent symptomatic venous thromboembolism compared to rivaroxaban in patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty?
Does extended prophylaxis with aspirin prevent symptomatic venous thromboembolism compared to rivaroxaban in patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty?
Extended prophylaxis with aspirin is not significantly different from rivaroxaban for preventing symptomatic VTE after hip or knee arthroplasty following an initial 5-day course of rivaroxaban.
Aspirin offers a comparable alternative to rivaroxaban for extended VTE prophylaxis after hip or knee arthroplasty; extends RCT evidence supporting its use in this setting.
Among patients who received 5 days of rivaroxaban prophylaxis after total hip or total knee arthroplasty, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism. (Funded by the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT01720108 .).
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2018) studied this question.